Procter & Gamble Valuation Questioned Amid Mixed Share Price Performance
Procter & Gamble's (PG) recent launch of its Oral-B iO product has put a spotlight on the company's premium oral care technology, sparking questions about how this innovation affects the stock's valuation.
The company's share price return has been mixed over the past quarter, with a 1.61% one-day gain but a softer 90-day return of 3.45%. Over the past year, Procter & Gamble's total shareholder return is down 5.29%, suggesting that momentum has cooled even as new products attempt to boost growth expectations.
Bulls point to the company's product engine and premium pricing power, while bears highlight recent underperformance and high expectations.
A valuation analysis suggests that Procter & Gamble may be overvalued by 35.1%, with a fair value of $107.52 compared to its current price of $145.27.